For medical or scientific enquiries or other enquiries, please contact us here:



Upper Polygon
Lower Polygone

The Association of the British Pharmaceutical Industry (ABPI) Code of Practice requires all companies to document and publicly disclose certain transfers of value (ToVs) made directly or indirectly to healthcare professionals (HCPs), other relevant decision makers (ORDMs) and healthcare organisations (HCOs) located in Europe, as well as to research & development (R&D) projects and patient organisations.

Working with HCPs/ORDMs and HCOs

Merz Therapeutics is committed to compliance and working within the ABPI Code of Practice and applicable laws. For payments made to HCPs/ORDMs and HCOs, including R&D projects in the last 3 years, please refer to the ABPI Disclosure Database:

Disclosure Database

Working with patient groups

Merz Therapeutics have also made the following contributions to working with patient groups:


Contributions to Patient Organisations in 2023


Dystonia UK


Support for the annual patient conference: “Dystonia Matters Live 2023”

The Stroke Association


Event Sponsorship

South West Parkinson’s Network, Parkinson’s UK


Meeting Sponsorship

Parkinson’s Europe (through Merz Pharma GmbH & Co KGaA)

€ 60,000

2023 Diamond Sponsorship



Contributions to Patient Organisations in 2022


Parkinson’s Europe, formerly EPDA (through Merz Pharma GmbH & Co KGaA)


2022 Diamond Sponsorship

Parkinson’s UK


Gold Plus sponsorship of Excellence Network conference



Contributions to patient organisations in 2021

Parkinson’s UK£20,600.00Education and training modules for healthcare professionals
Dystonia UK (through Merz Pharma GmbH & Co KGaA)£10,000.00Grant for animated educational video
European Parkinson’s Disease Association (through Merz Pharma GmbH & Co KGaA)£42,500.00EPDA’s 2021 Diamond Sponsorship


M-MT-UKI-0191 Date of Preparation June 2023